NGL Fine-Chem Ltd Company Fundamental Analysis

NGL Fine-Chem is a pharmaceutical company specialising in active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations, with a strong focus on veterinary medicines and selected human-health products. Its portfolio includes 32 APIs for veterinary and human use, and the company exports to more than 51 countries. Its integrated manufacturing capabilities and regulatory approvals provide opportunities to benefit from growing global animal-health demand and the China+1 sourcing trend. The expansion of its Tarapur manufacturing facility is intended to support additional production capacity and future growth. FY26 consolidated revenue increased 36% to approximately ₹501 crore, while net profit rose 128% to ₹48.1 crore, indicating a significant improvement in profitability. Q1 FY27 revenue reached ₹139.2 crore, up 33.6% year-on-year, while operating profit increased 112% to ₹23.3 crore and net profit rose 99% to ₹18.4 crore. Operating profitability improved considerably, with the operating margin reaching approximately 16.7%. However, the recently commissioned capacity will need to achieve healthy utilisation and customer demand to sustain this growth. The company also faces a GST notice for an alleged short payment of approximately ₹6.18 crore, which requires monitoring until resolved. At the latest available Groww data, NGL Fine-Chem had a market capitalisation of approximately ₹1,709 crore, P/E of 29.9x, P/B of 5.19x, ROE of 14.6% and debt-to-equity of 0.33x. Growth drivers include veterinary healthcare demand, export expansion, new manufacturing capacity and a wider product portfolio. Overall, NGL Fine-Chem has demonstrated strong earnings momentum and international reach, but sustaining margins and generating adequate returns from its new capacity will be essential to support its valuation.